GoodRx reports transitioning from injectable to oral GLP-1s can simplify weight loss routines, but requires careful timing ...

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

LMNT reports that GLP-1 medications for obesity and diabetes may lead to electrolyte imbalances, highlighting hydration ...

Xeris Pharmaceuticals has teamed up with the American Diabetes Association (ADA) to raise awareness of the importance of prescribing glucagon, positioning the partners to address a fundamental barrier ...

Weight-loss drugs such as Ozempic, Wegovy and Mounjaro work primarily by reducing hunger. They mimic a hormone the body ...

As the new year begins, many are using glucagon-like peptide-1 receptor agonists (GLP-1RAs) for weight loss. While effective, ...

Tirzepatide glaucoma risk was lower than with selective glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus ...

Glucagon prescriptions for severe hypoglycemia in Medicaid initially decreased from 2012 to 2018 but increased between 2019 and 2023 following the introduction of newer products. Glucagon ...

Nanosized particles that release glucagon, the hormone responsible for raising blood glucose levels, on-demand could mean that diabetics don’t need to worry about potentially dangerous low blood sugar ...

Lupin has received approval from the Food and Drug Administration for liraglutide injection single-patient-use prefilled pens and glucagon for injection vials. Both of these products will be ...

The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid. The FDA ...

People with diabetes take insulin to lower high blood sugar. However, if glucose levels plunge too low—from taking too much insulin or not eating enough sugar—people can experience hypoglycemia, which ...